

Sutro's Robust Pipeline of Product Candidates Demonstrates our Innovative Processes and Designed Intentionally to Expand Patient Benefit in Areas of High Unmet Need

PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2/3	WORLDWIDE OR GEOGRAPHIC PARTNER	
SUTRO-LED PROGRAMS								
Luveltamab tazevibulin (Luvelta, STRO-002)	FolR α Antibody-Drug Conjugate (ADC)	Ovarian Cancer	<i>Fast Track Designation</i>					 天士力生物 (Greater China Rights)
		Ovarian Cancer (bevacizumab combo)						
		Endometrial Cancer						
		CBF/GLIS2 Pediatric AML	<i>Orphan Drug & Rare Pediatric Disease Designation</i>					
		Adenocarcinoma, NSCLC						
STRO-001⁽¹⁾	CD74 ADC	B-cell Malignancies	<i>Orphan Drug Designation</i>				 BIONOVA Pharma 博诺医药 (Greater China Rights)	
STRO-003	ROR1 ADC	Solid Tumors & Hematological Cancers						
STRO-004	Tissue Factor ADC	Solid Tumors						
PARTNER PROGRAMS								
VAX-24	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease					 VAXCYTE <i>protect humankind</i>	
VAX-31	31-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						
MK-1484	Selective IL-2 Agonist	Advanced or Metastatic Solid Tumors					 MERCK	
Undisclosed Programs	Immunostimulatory ADCs (iADCs)	Cancers	<i>Multiple Programs</i>				 astellas	

1. Phase 1 dose escalation has completed in the U.S., and clinical development is ongoing in Greater China led by BioNova